Catherine S. Grasso

12.6k total citations · 2 hit papers
35 papers, 3.2k citations indexed

About

Catherine S. Grasso is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Catherine S. Grasso has authored 35 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 13 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Catherine S. Grasso's work include Cancer Genomics and Diagnostics (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Prostate Cancer Treatment and Research (6 papers). Catherine S. Grasso is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Prostate Cancer Treatment and Research (6 papers). Catherine S. Grasso collaborates with scholars based in United States, United Kingdom and Canada. Catherine S. Grasso's co-authors include Christopher Lee, Mark Sharlow, Xuhong Cao, Arul M. Chinnaiyan, Nallasivam Palanisamy, J. Chad Brenner, Christopher A. Maher, Antoni Ribas, Jennifer Tsoi and Xiaojun Jing and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Catherine S. Grasso

34 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression

2011 815 citations Saravana M. Dhanasekaran, Qi Cao et al. profile →
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

2018 583 citations Jennifer Tsoi, Lídia Robert et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine S. Grasso United States	18	2.2k	1.4k	652	612	270	35	3.2k
Pavel Sumazin United States	29	2.8k 1.3×	1.4k 1.0×	658 1.0×	411 0.7×	454 1.7×	68	4.1k
Xueyi Dong China	35	2.7k 1.2×	1.3k 0.9×	829 1.3×	318 0.5×	345 1.3×	79	3.7k
Yi-Mi Wu United States	16	3.1k 1.4×	2.4k 1.7×	750 1.2×	788 1.3×	242 0.9×	18	4.2k
Yue Peng China	24	2.1k 0.9×	770 0.6×	948 1.5×	479 0.8×	375 1.4×	86	3.2k
John W. Gillespie United States	27	3.7k 1.6×	892 0.7×	727 1.1×	687 1.1×	339 1.3×	55	4.9k
Peter M. Haverty United States	29	2.4k 1.1×	677 0.5×	846 1.3×	351 0.6×	298 1.1×	38	3.3k
Dariush Etemadmoghadam Australia	18	1.7k 0.7×	1.0k 0.7×	1.1k 1.7×	444 0.7×	304 1.1×	23	3.1k
Ran Brosh Israel	29	2.6k 1.2×	968 0.7×	1.5k 2.3×	336 0.5×	191 0.7×	45	3.7k
Fei Ji China	29	2.0k 0.9×	963 0.7×	570 0.9×	232 0.4×	157 0.6×	90	3.0k
Luca Quagliata Switzerland	29	1.7k 0.8×	1.4k 1.0×	640 1.0×	450 0.7×	446 1.7×	73	2.9k

Countries citing papers authored by Catherine S. Grasso

Since Specialization

Citations

This map shows the geographic impact of Catherine S. Grasso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine S. Grasso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine S. Grasso more than expected).

Fields of papers citing papers by Catherine S. Grasso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine S. Grasso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine S. Grasso. The network helps show where Catherine S. Grasso may publish in the future.

Co-authorship network of co-authors of Catherine S. Grasso

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine S. Grasso. A scholar is included among the top collaborators of Catherine S. Grasso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine S. Grasso. Catherine S. Grasso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

You, Sungyong, Yanping Wang, Patrick Tamukong, et al.. (2022). PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration. Cancer Letters. 555. 216034–216034. 16 indexed citations

Kim, Yeon Joo, Katherine M. Sheu, Jennifer Tsoi, et al.. (2021). Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapy. Journal of Clinical Investigation. 131(12). 40 indexed citations

You, Sungyong, Minhyung Kim, Junhee Yoon, et al.. (2020). Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. BMC Cancer. 20(1). 398–398. 10 indexed citations

Wang, Xiaoyu, Catherine S. Grasso, Kristina M. Jordahl, et al.. (2020). Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer and Prostatic Diseases. 23(3). 494–506. 11 indexed citations

Paz, Helicia, Jennifer Tsoi, Anusha Kalbasi, et al.. (2019). Interleukin 32 expression in human melanoma. Journal of Translational Medicine. 17(1). 113–113. 12 indexed citations

Ribas, Antoni, Donald P. Lawrence, Victoria Atkinson, et al.. (2019). Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nature Medicine. 25(6). 936–940. 230 indexed citations

Tsoi, Jennifer, Lídia Robert, Kim H.T. Paraiso, et al.. (2018). Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 33(5). 890–904.e5. 583 indexed citations breakdown →

Nowicki, Theodore S., Beata Berent-Maoz, Rong Huang, et al.. (2018). Abstract CT008: A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab in patients with sarcoma and melanoma. Cancer Research. 78(13_Supplement). CT008–CT008. 2 indexed citations

Fu, Xiaoyong, Li Zhao, Catherine S. Grasso, et al.. (2017). Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities. Molecular and Cellular Endocrinology. 471. 105–117. 21 indexed citations

10.

Cani, Andi K., Daniel H. Hovelson, Andrew S. McDaniel, et al.. (2015). Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors. Molecular Cancer Research. 13(4). 613–619. 97 indexed citations

11.

Grasso, Catherine S., Timothy Butler, Katherine Rhodes, et al.. (2014). Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data. Journal of Molecular Diagnostics. 17(1). 53–63. 85 indexed citations

12.

McDaniel, Andrew S., Yali Zhai, Kathleen R. Cho, et al.. (2014). HRAS mutations are frequent in inverted urothelial neoplasms. Human Pathology. 45(9). 1957–1965. 27 indexed citations

13.

Kothari, Vishal, Sunita Shankar, Shanker Kalyana‐Sundaram, et al.. (2013). Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy. Cancer Discovery. 3(3). 280–293. 29 indexed citations

14.

Lonigro, Robert J., Catherine S. Grasso, Dan R. Robinson, et al.. (2011). Detection of Somatic Copy Number Alterations in Cancer Using Targeted Exome Capture Sequencing. Neoplasia. 13(11). 1019–IN21. 55 indexed citations

15.

Yu, Jian, Qi Cao, Longtao Wu, et al.. (2010). The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene. 29(39). 5370–5380. 66 indexed citations

16.

Grasso, Catherine S., et al.. (2004). Computational Analysis of Sequence Selection Mechanisms. Structure. 12(4). 547–557. 12 indexed citations

17.

Grasso, Catherine S. & Christopher Lee. (2004). Combining partial order alignment and progressive multiple sequence alignment increases alignment speed and scalability to very large alignment problems. Bioinformatics. 20(10). 1546–1556. 93 indexed citations

18.

Grasso, Catherine S., et al.. (2003). GENOME-WIDE DETECTION OF ALTERNATIVE SPLICING IN EXPRESSED SEQUENCES USING PARTIAL ORDER MULTIPLE SEQUENCE ALIGNMENT GRAPHS. PubMed. 29–41. 16 indexed citations

19.

Lee, Christopher, Catherine S. Grasso, & Mark Sharlow. (2002). Multiple sequence alignment using partial order graphs. Bioinformatics. 18(3). 452–464. 399 indexed citations

20.

Daida, Jason M., Catherine S. Grasso, Stephen A. Stanhope, & Steven J. Ross. (1996). Symbionticism and Complex Adaptive Systems I: Implications of Having Symbiosis Occur in Nature.. 177–186. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact